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Abstract. We review the major hemorheological experimental studies that show the erythrocyte aggregation as a link between
basic and clinical research. The results of the clinical cross-sectional and longitudinal studies presented here will highlight the
possible association between erythrocyte aggregation and plasma fibrinogen. Basic studies conducted in vitro are also mentioned
as for its relevance in answering questions raised in clinical settings, as well as and in understanding the underlying influent
factors in the erythrocyte tendency to aggregate and disaggregate.
1. Introduction
In blood circulation the erythrocyte has the mission to furnish the tissues with oxygen and nitric oxide
and receive the carbon dioxide in return [70]. To attain the gas exchange, at the microcirculation network,
it is necessary to hold a proper blood flow cardiac output, vessel wall integrity, regulation of blood flow
in the microvascular architecture network and normal blood viscosity [7, 30, 42, 53]. The tendency of
red blood cells (RBCs) to aggregate and disaggregate is an influent factor in the rheological blood flow
viscosity behaviour [9].
The increase of erythrocyte aggregation intensifies the microvascular flow resistance, fills capillaries
(become with no flow) and at lower shear rates like in the venous circulation, the aggregation of red
blood cells affects the blood velocities profile and increases blood viscosity [9, 34, 45]. Biomolecular,
mechanical and physical factors influence RBCs aggregation and can be divided into: (i) extrinsic factors
including the levels of plasma proteins (e.g. fibrinogen, lipoproteins, macroglobulins or immunoglob-
ulins), hematocrit, particle size, plasma osmolality (particle number) and shear rate; and (ii) intrinsic
factors e.g. RBCs shape, deformability and membrane surface properties [28, 48, 56, 69]. RBC sur-
face properties and structure, such as surface charge and the ability of macromolecules to penetrate the
membrane glycocalyx, greatly affect aggregation for cells suspended in a defined medium [18, 47].
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In the next sections we review some human pathological situations where increased levels of erythrocyte
aggregation were found and also a few studies developed in vitro for the manipulation of the RBCs
tendency to aggregate.
1.1. Cross-sectional clinical studies
The clinical studies trying to evaluate hemorheological parameters and discover their correlations with
patient symptoms, lipid profile, hemodynamic, haemostatics and inflammatory factors, started in the last
century.
We have verified that in a heterogeneous group of glaucoma patients, predominantly with chronic open
angle, the erythrocyte aggregation is augmented [55]. Similar results were pointed by others later, in
patients with normal tension glaucoma [17, 74]. The great tendency of the red blood cells to aggregate
allied to other hemorheological dysfunctions favour the developing of abnormalities at the microcir-
culation levels and damage of the optic nerve and consequently worsening the ocular blood flow [17,
74].
In a group of patients with chronic renal failure being submitted to chronic haemodialysis the erythrocyte
aggregation index do not show significant difference when compared with the control group matched
in age and gender, in spite of the increase fibrinogen levels observed in patients [6]. Apparently in this
study the fibrinogen effect on erythrocyte aggregation tendency is surpassed by other influent factors
mentioned above or by the anemia that favours the absence of changes in this red blood cell rheological
property. The same apparent lack of influence was obtained in a group of renal transplant recipients where
fibrinogen levels were similar to the control group but the erythrocyte aggregation has higher values in
the recipients [4].
Other authors also verified an increase of RBCs aggregation in a group of renal transplant patients [20].
The aetiology of chronic renal failure is diverse and, consequently, when patients are submitted to kidney
transplantation they do not sustain a homogeneous hemorheological behaviour. The recipients between
them exhibited dissimilarities allied to the ocurrence of self immune system adaptation and inflammatory
response [16, 21].
In a group of hypertensive patients with eye vascular dysfunctions, that were admitted to hospital,
we have observed an increase in erythrocyte aggregation and of plasma fibrinogen concentrations [11].
The RBCs hyperaggregation obtained by us in these patients may be an underlying present factor in the
reduction of peripheral tissue oxygenation verified by other authors in severe hypertensive patients [19].
We will come back to the results of our study [11] below on the topic of longitudinal studies.
In general, in hypertension several structural dysfunctions can occur like heart hypertrophy, fibrosis
as well as at microcirculation where elevation of artery stiffness, impairment of artery remodelling and
microvascular rarefaction may be present at different degrees of severity [10]. It was verified by Jung
[31] that patients with long term essential hypertension when evaluated by intravital microscopy and the
intramuscular by pO2 needle electrode, some present with primary microcirculatory disorders and others
secondary disorders. In a previous work with patients with essential hypertension and renal dysfunction
Jung [32] verified that when the number of capillaries per millimetre of epidermis are increased, the degree
of retinal vascular changes (fundus hypertonicus) are more severe. Erythrocyte aggregation and plasma
viscosity were elevated in those patients being the degree of retinal vascular alteration associated with
plasma viscosity [32]. Changes in myogenic, metabolic, hormonal and trophic regulatory mechanisms
present in vessel walls occur especially in those high perfused organs with low vascular resistance such
as kidney, heart and brain. In general, aged humans have elevation of blood pressure, increased plasma
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fibrinogen, elevated platelet aggregability and augmented blood viscosity [14, 35, 38]. In spite of these
evidences we conducted a hemorheological and cardiological study with normontensives elderly people
[49]. This group presents both erythrocyte aggregation and fibrinogen values lower than younger age
matched individuals without statistical significance [49]. The elderly group has spent a healthy happy
past life with regular and moderate exercise and balanced intake diet [49].
In women with pregnancy-induced hypertension it was verified an increased RBCs aggregation and
adhesiveness despite the absence of incremented fibrinogen level [25].
The authors in this work did not find any association between those hemorheologycal variables as
opposed to other authors who reported that in a longitudinal study conducted with normal pregnant
women both parameters increase and are associated [30]. Hemorheological study reported in women
with preeclampsia reveal increased erythrocyte aggregation [72] but after therapeutic submission the
high RBCs tendency to aggregate shows a reduction with labetalol and regression to the normal values
with nifedipine [73].
The impairment of blood flow in macrocirculation caused by arteriosclerosis is a major determinant
of microcirculation perfusion in coronary artery disease (CAD). Groups of patients with CAD with
diagnostic of unstable or stable angina pectoris or with chest pain at hospital admission, before submission
to fibrinolytic or any medical intervention, were studied [52]. In these groups of patients it was reported
an increase in erythrocyte aggregation tendency and enhanced plasma levels of C-reactive protein and
fibrinogen. The three parameters are considered indicators of cardiovascular disease [52]. The authors
propose that increased RBCs aggregation seems unlike to contribute to the emergence of AMI [52]. The
study conducted by Liuni [39] with healthy human volunteers in which ischemia/reperfusion injury was
performed, has proved it does induce cardiovascular protection resulting from the administration of a
HMG-CoA reductase inhibitor.
In the Aachen study three groups of patients namely with peripheral occlusive arterial disease, coronary
artery disease and cerebrovascular insufficiency were evaluated and the results showed no differences
among them in respect to the erythrocyte aggregation tendency and plasma fibrinogen concentration [37].
Actually, these values are higher when compared with those obtained in the healthy control group [37].
In the TAMCIS cross-sectional study a strong association was evidenced between the atherothrombotic
risk factors and the degree of erythrocyte aggregation [3]. Other well important finding is the clear associ-
ation between plasma fibrinogen levels and erythrocyte aggregation tendency at low grade inflammation
manifested by the patients, whereas where serum lipids influence was only a minor determinant [3, 24,
57, 77]. Another study in patients with atherothrombotic risk factors evidenced differences in gender
profile having women significant higher values of erythrocyte aggregation than man with matched age
[76].
The association between the strength of large RBCs aggregates and the inflammatory status and the
high plasma fibrinogen concentration was also observed in patients with inflammatory bowel disease
where a detrimental microcirculatory blood flow is present in the intestinal microvasculature [41].
1.2. Longitudinal clinical studies
In cross-sectional studies any biomolecule, cell property or cell function may not be considered a cause
or a consequence for a disease neither named like a prognostic marker of further pathological events to
occur in patients.
Beyond the rheological cross-longitudinal approach, follow-up studies have been developed and herein
we will mention some of them.
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The above referred study [11] conducted in hypertensive patients with vascular dysfunctions at the ocu-
lar level, after admission to hospital, were followed during 45 days. At hospital discharge patients showed
normal tensional levels, regression of the ophthalmological vasoconstriction to the normal values and
improvement of the electrocardiographic dysfunction. However, the hemorheological parameters plasma
viscosity and hematocrit decreased while the erythrocytes maintained the high tendency to aggregate
which may be related to the intrinsic RBCs properties reported in hypertensive patients [12, 19, 23, 36,
44, 58].
A hemorheological clinical follow-up project of the Portuguese Society of Hemorheology and Micro-
circulation in association with the Lisbon Medical School (Biochemistry Institute and the Cardiology
Department, UTIC-AC) was established and survivors of acute transmural myocardial infarctions were
consecutively enrolled from 1994 to 1999, with clinical and cardiological evaluation and hemostatic,
inflammatory and hemorheological parameters assessment at 6, 12, 24, 36 and 60 months [61, 63, 66–68].
During this period of time, the survivors were divided into two groups of patients according to the
occurrence of cardiovascular events. At hospital discharge those patients that presented higher leukocytes
count, higher leukocyte elastase enzyme activity, higher PAI-1, higher erythrocyte membrane viscosity,
lower protein C activity or lower erythrocyte aggregation tendency, were found to develop cardiovascular
events [61, 63, 66–68]. The absence of an association between erythrocyte aggregation and fibrinogen
verified at hospital discharge appeared at 6 and at 12 months in an inverse relationship. The same behaviour
was obtained between PAI-1 and fibrinogen and between PAI-1 and plasma viscosity. The decrease
of erythrocyte aggregation tendency determined at hospital discharge may result from the membrane
rigidity determined in these patients [61]. The association observed between erythrocyte aggregation and
inflammatory response (leukocyte elastase activity) and with hemostatic parameter (PAI-1) may explain
the thrombotic events that occurred in the survivors. It is known that the presence of erythrocyte aggregates
slow down the blood flow, reduce the level of capillary density and increase resistance to blood flow [9, 33,
75]. Until 60 months of follow-up some haemostatic, hemorheological and inflammatory disturbances,
at hospital discharge, seem to be long-term independent predictors of recurrent cardiovascular events in
transmural myocardial infarction survivors [61, 63, 66–68].
Others have observed different patterns of erythrocyte aggregates mainly following the onset of pain
prior to the event of infarction and advertise not to delay the medical intervention in these patients [71].
From the “Sicilian Study on Juvenile Myocardial Infarction”, Caimi [13] presented the hemorheolog-
ical results obtained from young adults before and after three months of acute myocardial infarction.
The erythrocyte aggregation tendency did not show any variation between the two AMI stages neither
between the patients assigned to groups with less of 2 or more than 2 risk factors, as well as between
the groups assigned to 1 vessel or 2–3 vessels disease. In a case control study [78] of young patients
with AMI aged less than forty five years old, subjects were submitted to the evaluation of hemorhe-
ological parameters and lipid profile between the third month and the first year after the occurrence
of the event. No differences in the hemorheological parameters were verified between patients with
differences on AMI type, on number and scores of stenosed vessels. In all patients erythrocyte aggre-
gation, fibrinogen and triglycerides presented higher values than the control group, and the two last
parameters, after multivariate adjustment were independently associated with the erythrocyte aggregation
[5].
The anemia exhibited by patients with chronic renal failure on regular haemodyalysis was followed
before and after three months of treatment with recombinant human erythropoietin [43]. A signifi-
cant increase in the haemoglobin values was obtained despite no variations were verified in the RBCs
aggregation [43].
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A group of fourteen patients with familial hypercholesterolemia were treated with lovastatin for three
months and the RBCs aggregation, and phospholipid membrane and lipid profile determined. After the
intake of lovastatin there was a reduction in the plasma concentration of cholesterol and LDL cholesterol
and this change correlates with a significant decrease in the membrane cholesterol/phospholipid ratio of
the red blood cell membrane. The variation in the lipid composition verified is statistically related to the
decrease in erythrocyte aggregability assessed [54].
From cross-sectional and longitudinal studies erythrocyte aggregation is (i) considered an independent
risk factor for AMI, increasing over time in transmural myocardial survivors, (ii) evidenced as an inde-
pendent predictor of recurrent cardiovascular events [67, 68, 78], and (iii) associated with inflammation
response [41, 52].
Fibrinogen is also present at high levels in plasma of inflammatory diseases, thereby being considered
a acute phase protein [8] and demonstrated by Lominadze as a pro-inflammatory factor responsible for
vascular dysfunction [40].
1.3. Basic “in vitro” studies
From the clinical settings there is no evidenced for a consistently direct or indirect relationship between
the profile values of erythrocyte aggregation and fibrinogen. The polymorphism of the -fibrinogen
gene observed in healthy individuals is associated with differences is gender propensity to erythrocyte
aggregation [8]. Others have suggested that in addition to fibrinogen, C-reactive protein may be an influent
factor in enhancing the erythrocyte aggregation which present in inflammation and cardiovascular disease
[64]. The authors propose that it must be (i) differentiated the contribution between the plasmatic and
cellular factors and (ii) provided and determined the size of aggregates and the strength of the intercellular
interaction [2]. Falco´ attributed to erythrocyte aggregation apparatus used for its determination, the
absence of its association with plasma fibrinogen concentration higher than 400 mg/dL [22].
We will present results obtained from in vitro studies that bring insights for the influence of fibrinogen on
erythrocyte aggregation tendency with or without biological compounds in blood of healthy individuals
and patients. Our approach was based on the dependence of the RBCs aggregation from their own
properties and from the plasma composition.
We have verified in blood samples taken from healthy men that when enriched with fibrinogen the
erythrocyte aggregation tendency increases [64]. The same behaviour was verified in the presence of
oubain (a Na+, K+ ATPase inhibitor) relatively to the oubain-and-fibrinogen –free control, as well as
when compared with the fibrinogen-free control. There was no statistically significant difference in
erythrocyte aggregation in aliquots with fibrinogen in absence or presence of oubain. From this study
we may conclude that the increasing fibrinogen concentration are related to an increase in erythrocyte
aggregation, thereby seeming not to be connected with the erythrocyte oubain-sensitive Na+, K+ ATPase
[26].
Pursuing our approach to study the erythrocyte membrane proteins, we focused on band 3 protein
phosphorylation degree which was manipulated by using inhibitors of protein tyrosine kinase and protein
tyrosine phosphatase [62]. Using blood samples from healthy individuals with plasma fibrinogen at
normal range, the RBCs aggregation was found to be higher when band 3 is phosphorylated than when
dephosphorylated besides both band 3 states have lower values than the control aliquot. The band 3 protein
phosphorylation status becomes an intrinsic influent factor in this erythrocyte rheological property [62].
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The stimulation of the erythrocyte redox status by adding dithiothreitol in blood samples taken from
healthy humans with normal values of plasma fibrinogen, revealed no changes in RBCs aggregation [1].
The increase in nitric oxide (NO) efflux and mobilization occurred in RBCs when in presence of
acetylcholine and the enhance RBCs NO influx occur by the effect of Spermine NONOate [48]. This gas
movement induces respectively a decrease or maintenance of RBCs aggregation tendency in blood sam-
ples of healthy donors with normal values of plasma fibrinogen [48]. A signal transduction mechanism
that includes Gi protein to explain increase erythrocyte tendency under effects of acetylcholine or stimuli
on Gi protein itself was pointed by us and Moravyov et al. [15, 50]. The last group of authors shows
that stimulating the calcium influx and the adenylyl cyclase –cAMP system increases the aggregation
of the RBCs [51]. Blood samples were obtained from women undergoing transdermic 17-estradiol (50
g/diarly). From incubations of blood aliquots with 17-estradiol 10−5 M, two sub-groups with high and
low RBCs membrane fluidity were obtained which showed increase osmolality and decreased erythro-
cyte aggregation [27]. Some unknown molecular effect nullifies the direct positive effect of increased
osmolality on the RBCs tendency to aggregate [59]. We verified by fluorescence spectroscopy the alter-
ation on fibrinogen molecule conformation by binding of 17-estradiol with high affinity (association
constant = 6.47 × 106 M−1) [60]. Other molecular interactions may occur between therapeutically circu-
lating plasma molecules and fibrinogen that justify diverse kinds of association or lack of them between
fibrinogen levels and RBCs aggregation tendency. For example we studied a group of hypercholestre-
olemic patients submitted during three months to lovastatin therapy that does not show any changes in
the erythrocyte aggregation tendency [65]. However when blood samples taken before treatment onset
where incubated with different lovastatin concentration a decrease of the RBCs aggregation tendency
was observed [65].
Beyond the effects of blood mechanical factors, plasma substances and intrinsic erythrocyte properties
influence on RBCs aggregation in vivo, or in vitro others factors must be taken into account. So, there
must be considered for example (i) different apparatus for its measurement and (ii) the concepts of RBCs
aggregation and RBCs aggregability defined by Meiselman who dedicates great part of his research (more
than 45 years) in the field of erythrocyte aggregation [46].
Al the studies reported in this review was referred to erythrocyte aggregation.
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